Viatris, Inc. (VTRS)
17.09
+0.46
(+2.77%)
USD |
NASDAQ |
Sep 02, 16:00
17.09
0.00 (0.00%)
After-Hours: 17:53
Viatris Research and Development Expense (TTM) : 995.00M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 995.00M |
| March 31, 2026 | 965.80M |
| December 31, 2025 | 941.10M |
| September 30, 2025 | 886.70M |
| June 30, 2025 | 839.40M |
| March 31, 2025 | 827.50M |
| December 31, 2024 | 806.70M |
| September 30, 2024 | 801.10M |
| June 30, 2024 | 814.80M |
| March 31, 2024 | 819.00M |
| December 31, 2023 | 802.20M |
| September 30, 2023 | 783.40M |
| June 30, 2023 | 747.10M |
| March 31, 2023 | 701.40M |
| December 31, 2022 | 660.80M |
| September 30, 2022 | 734.10M |
| June 30, 2022 | 712.30M |
| March 31, 2022 | 693.50M |
| December 31, 2021 | 714.20M |
| September 30, 2021 | 613.20M |
| June 30, 2021 | 589.80M |
| March 31, 2021 | 602.10M |
| December 31, 2020 | 553.10M |
| September 30, 2020 | 551.60M |
| June 30, 2020 | 589.80M |
| Date | Value |
|---|---|
| March 31, 2020 | 581.30M |
| December 31, 2019 | 639.80M |
| September 30, 2019 | 636.20M |
| June 30, 2019 | 612.10M |
| March 31, 2019 | 659.40M |
| December 31, 2018 | 686.90M |
| September 30, 2018 | 741.10M |
| June 30, 2018 | 779.60M |
| March 31, 2018 | 765.80M |
| December 31, 2017 | 783.30M |
| September 30, 2017 | 775.50M |
| June 30, 2017 | 792.30M |
| March 31, 2017 | 790.70M |
| December 31, 2016 | 826.80M |
| September 30, 2016 | 791.20M |
| June 30, 2016 | 766.90M |
| March 31, 2016 | 755.60M |
| December 31, 2015 | 671.90M |
| September 30, 2015 | 663.10M |
| June 30, 2015 | 646.50M |
| March 31, 2015 | 633.70M |
| December 31, 2014 | 581.80M |
| September 30, 2014 | 561.41M |
| June 30, 2014 | 515.90M |
| March 31, 2014 | 471.04M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Pfizer Inc. | 10.82B |
| Eli Lilly & Co. | 14.60B |
| Merck & Co., Inc. | 27.26B |
| Bristol Myers Squibb Co. | 9.548B |
| Johnson & Johnson | 15.06B |